Annuncio • Apr 07
hVIVO plc to Report Fiscal Year 2025 Final Results on Apr 15, 2026 hVIVO plc announced that they will report fiscal year 2025 final results at 8:00 AM, GMT Standard Time on Apr 15, 2026 Annuncio • Nov 27
hVIVO plc Announces Positive Results from Phase IIb Trial hVIVO plc congratulates its client Cidara Therapeutics Inc. which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve /AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis. Annuncio • Nov 11
hVIVO plc Presents Positive Data from Multiple Novel Human Challenge Models hVIVO plc announced key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza ("ESWI") Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models, all demonstrating an acceptable safety and tolerability profile, reinforcing hVIVO's continued capabilities in accelerating the development of novel challenge agents and its readiness to meet customer demand for innovative and effective clinical trial solutions. Human Metapneumovirus ("hMPV") challenge model hVIVO's Senior Study Physician, Dr Alexander Lima, presented the positive findings from the newly developed, and world's only contemporary-strain hMPV human challenge model. The presentation at ESWI, titled, " Disease characteristics and immunological profiles obtained from newly developed hVIVO human challenge model", highlighted the model's strong performance using a recent 2a strain, which compared favourably against hVIVO's established RSV A model, a benchmark for model performance for this particular virus family. The model demonstrated high infection and symptomatic disease attack rates and robust AUC virology by qRT-PCR, and is now ready and available for vaccine and antiviral human challenge trials. SARS-CoV-2 Omicron challenge model Alex Mann, Senior Director Clinical Science presented, " Development of a SARS-CoV- 2 Omicron BA5 human challenge mode l" at ESWI. A key insight from the presentation was the importance of timing of dosing post-inoculation, particularly in the context of post-exposure prophylaxis. This represents the first commercially available Omicron human challenge model. Respiratory Syncytial Virus B (RSV B) challenge model At the World Vaccine Congress Europe, hVIVO's Chief Scientific Officer, Dr Andrew Catchpole showcased the positive results from hVIVO's new RSV B model titled, " High infection rates achieved with the world' first RSV B challenge models key component of the RSV-hMPV-PIV combination vaccine efficacy testing platform. The data confirmed the robustness of the RSV B model, which is now available for vaccine and anti-viral efficacy testing. The development of the RSV B and hMPV models, along with the Company's collecting of PIV (parainfluenza virus) clinical samples, has enabled the Company to create a comprehensive efficacy testing platform enabling the Company to test individual components of the next generation combination vaccines under development. Annuncio • Sep 04
hVIVO plc to Report Q2, 2025 Results on Sep 23, 2025 hVIVO plc announced that they will report Q2, 2025 results on Sep 23, 2025 Annuncio • Sep 01
Hvivo plc Appoints Shaun Chilton to Board of Directors as Non-Executive Chair with Effect from September 1, 2025 hVIVO plc Shaun Chilton has joined the Board of Directors as Non-Executive Chair with immediate effect. Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group. The following additional information is provided with regards to the appointment of Shaun Edward Chilton, aged57, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies: Current directorships/partnerships: Avacta Group plc; Bellbrook Consulting Limited; Mustang Bidco Limited; Mustang Midco Limited; Mustang Topco Limited. Former directorships/partnerships (within the last five years): C7 Health Limited; Clinigen Clinical Trials Limited; Clinigen Consulting Limited; Clinigen CTS Limited; Clinigen Gap Limited; Clinigen Healthcare Limited; Clinigen Holdings Limited; Clinigen International Holdings Limited; Clinigen Limited; Clinigen Pharma Limited; Definigen Limited; IDIS GA Limited; IDIS Group Holdings Limited; IDIS Group LimitedIDIS Limited; IDIS MA Limited; IDIS Pharma Limited; Iovance Biotherapeutics UK SP Ltd; Keats Healthcare Limited. Annuncio • Jul 18
hVIVO plc Announces Resignation of Tracey James as Non-Executive Director, Effective 18 July 2025 hVIVO plc announced that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect (18 July 2025). The Company confirmed that Ms. James' decision to resign from the Board is unrelated to the Company's financial performance or outlook. The Nominations Committee has commenced a process to appoint a new independent Non-Executive Director, and the Company will announce the results of this process in due course. Separately, the Nominations Committee is progressing well in its process to appoint a new independent Non-Executive Chair, with a further announcement to be made in due course. Annuncio • May 13
hVIVO plc, Annual General Meeting, Jun 05, 2025 hVIVO plc, Annual General Meeting, Jun 05, 2025. Location: the offices of cavendish capital markets ltd, 1 bartholomew close, ec1a 7bl, london United Kingdom Annuncio • Mar 21
hVIVO plc to Report Fiscal Year 2024 Results on Apr 10, 2025 hVIVO plc announced that they will report fiscal year 2024 results at 11:00 AM, GMT Standard Time on Apr 10, 2025 Annuncio • Feb 27
hVIVO plc (AIM:HVO) acquired Cryo Store Limited. hVIVO plc (AIM:HVO) acquired Cryo Store Limited on February 27, 2025. Under the terms of the Acquisition, three managers of Cryostore will be issued up to 2,773,982 ordinary shares of £1p each in hVIVO ('Consideration Shares') with an aggregate value of up to £0.5 million at the average closing share price for the ten days prior to 24 February 2024. 1,386,991of the Consideration Shares (being 50%) will be allotted on the 12-month anniversary of completion with1,386,991 of the Consideration Shares (being 50%) being allotted on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group at the time of the allotments. For the period ending December 31, 2024, Cryo Store Limited reported total revenue of £0.89 million and EBITDA of £0.52 million. As of December 31, 2024, Cryo Store Limited reported total common equity of £0.84 million. Geoff Nash, Camilla Hume, Harriet Ward, Nigel Birks, Louise Talbot of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc.
hVIVO plc (AIM:HVO) completed the acquisition of Cryo Store Limited on February 27, 2025. Annuncio • Jan 31
hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million. hVIVO plc (AIM:HVO) acquired Two Clinical Research Units of Crs Clinical Research Services Management GmbH for €10 million on January 29, 2025. Under the terms of agreement, the Acquisition has been completed for a cash consideration of €10.0 million, wholly funded from the Group's existing cash resources. For the period ending December 31, 2024, The Mannheim and Kiel units recorded unaudited revenues of €19.9 million, with an adjusted EBITDA loss of €1.8 million. Under hVIVO's ownership the two units will undergo an investment and restructuring programme to assist with their integration which is expected to cost c.€2.5 million in 2025 including net liabilities being acquired of less than €0.5 million. Following the Acquisition, average contract sizes across the Group are anticipated to increase, as well as growth in the CRS sales pipeline. The current senior leadership team at CRS, consisting of Dr. Elisabeth Lackner, Chief Executive Officer; Catherine Canales, Chief Commercial Officer; Prof. Dr. Thomas Forst, Chief Medical Officer; and Till Mieskes, Chief Financial Officer, will continue in their roles. The Acquisition expected to be earnings accretive in 2026. The integration of the Acquisition into the wider Group is expected to impact EBITDA margins in the short term and the Group expects to deliver strong revenue growth in 2026 and a significant improvement on EBITDA margins following the integration of CRS.
Geoff Nash and Camilla Hume of Cavendish Capital Markets Limited acted as financial advisor for hVIVO plc.
hVIVO plc (AIM:HVO) completed the acquisition of Two Clinical Research Units of Crs Clinical Research Services Management GmbH on January 29, 2025. Annuncio • Aug 20
hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024 hVIVO plc announced that they will report first half, 2024 results on Sep 10, 2024 Annuncio • Aug 05
hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth hVIVO plc announced its intention to cancel its admission ("the Cancellation") to trading on Euronext Growth. As hVIVO's primary operations, along with the majority of its employees and investor base, are in the UK,the Board has decided to consolidate trading of the Company's stock to its primary listing on the AIM Market of the London Stock Exchange. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on hVIVO's Ordinary Shares which will continue to trade on AIM under the ticker "HVO". In accordance with the Euronext Growth Rules, the Company has notified Euronext of the proposed Cancellation. Under the Euronext Growth Rules, the Cancellation can only take place after the expiry of a minimum period of twenty Business Days from the date on which notice of the Cancellation is given. Accordingly, it is intended that the Cancellation will become effective at 7.00 a.m. on 2 September 2024. Annuncio • Apr 16
hVIVO plc, Annual General Meeting, May 13, 2024 hVIVO plc, Annual General Meeting, May 13, 2024, at 10:00 Coordinated Universal Time. Annuncio • Mar 27
hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024 hVIVO plc announced that they will report fiscal year 2023 results on Apr 09, 2024 Annuncio • Feb 15
hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million. hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,955,178
Price\Range: £0.28
Transaction Features: Subsequent Direct Listing Annuncio • Jan 02
hVIVO plc Signs £6.3 Million Human Challenge Study Model hVIVO plc announced that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV - common cold virus) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the Company's new specialist quarantine facilities in Canary Wharf. It will evaluate the effect of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against HRV infection in multiple cohorts of healthy volunteers. The study is expected to commence in H2 2024, with revenue recognised in 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers via the Company's dedicated volunteer recruitment arm, FluCamp. This biotechnology client recognises the benefit of human challenge in quickly generating early human efficacy data, which has the potential of significantly enhancing the value of their clinical asset. Human rhinoviruses (HRV) are a group of pathogens that cause 'the common cold', with over 150 distinct types of HRV currently known. Although one third of HRV infections are asymptomatic, it can be potentially serious in the elderly, immunocompromised and those with existing respiratory diseases, and there is strong evidence of a relationship between HRV infection and more severe symptoms of asthma and COPD. To date, no antiviral has been approved in the prevention or treatment of HRV infection. Annuncio • Sep 12
hVIVO plc Increases Revenue Guidance for 2023 The Board of hVIVO plc has increased its revenue guidance to £55 million for 2023. Annuncio • Aug 24
hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023 hVIVO plc announced that they will report first half, 2023 results on Sep 12, 2023 Annuncio • Jun 30
hVIVO plc to Develop Human Metapneumovirus Challenge Model hVIVO plc is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate. hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in first half 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from second half of 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024. The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide. Up to 16% of the children infected with hMPV develop more severe symptoms2, with over 16,000 deaths worldwide in children under the age of five each year. Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV. Annuncio • Jan 25
hVIVO plc Provides Earnings Guidance for the Full Year 2022 hVIVO plc provided earnings guidance for the full year 2022. The group expected to report record full year revenues of £50.6 million (2021: £39 million), a 30% increase year-on-year. The significant growth in revenue provides further validation of the long-term sustainable growth in the human challenge trial market, for which hVIVO is the world leader.